138 related articles for article (PubMed ID: 30608334)
41. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
[TBL] [Abstract][Full Text] [Related]
42. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
[TBL] [Abstract][Full Text] [Related]
43. Mechanism of human urotensin II-induced contraction in rat aorta.
Tasaki K; Hori M; Ozaki H; Karaki H; Wakabayashi I
J Pharmacol Sci; 2004 Apr; 94(4):376-83. PubMed ID: 15107577
[TBL] [Abstract][Full Text] [Related]
44. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
[TBL] [Abstract][Full Text] [Related]
45. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure.
Oh KS; Lee JH; Yi KY; Lim CJ; Park BK; Seo HW; Lee BH
Eur J Pharmacol; 2017 Mar; 799():94-102. PubMed ID: 28163023
[TBL] [Abstract][Full Text] [Related]
46. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
[TBL] [Abstract][Full Text] [Related]
47. Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway.
Gao S; Shah A; Oh YB; Park WH; Kim SH
Peptides; 2010 Jan; 31(1):164-9. PubMed ID: 19896516
[TBL] [Abstract][Full Text] [Related]
48. Urotensin II: the old kid in town.
Onan D; Hannan RD; Thomas WG
Trends Endocrinol Metab; 2004; 15(4):175-82. PubMed ID: 15109617
[TBL] [Abstract][Full Text] [Related]
49. The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues.
Zeng ZP; Liu GQ; Li HZ; Fan XR; Liu DM; Tong AL; Zheng X; Liu C
Ann N Y Acad Sci; 2006 Aug; 1073():284-9. PubMed ID: 17102097
[TBL] [Abstract][Full Text] [Related]
50. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.
Chatenet D; Nguyen QT; Létourneau M; Dupuis J; Fournier A
Biochem Pharmacol; 2012 Mar; 83(5):608-15. PubMed ID: 22197588
[TBL] [Abstract][Full Text] [Related]
51. Ligand-supported purification of the urotensin-II receptor.
Du AT; Onan D; Dinh DT; Lew MJ; Ziogas J; Aguilar MI; Pattenden LK; Thomas WG
Mol Pharmacol; 2010 Oct; 78(4):639-47. PubMed ID: 20647393
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist.
Chi YH; Lee JH; Kim JH; Tan HK; Kim SL; Lee JY; Rim HK; Paik SH; Lee KT
Biol Pharm Bull; 2013; 36(7):1208-15. PubMed ID: 23811571
[TBL] [Abstract][Full Text] [Related]
53. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.
Liu Q; Pong SS; Zeng Z; Zhang Q; Howard AD; Williams DL; Davidoff M; Wang R; Austin CP; McDonald TP; Bai C; George SR; Evans JF; Caskey CT
Biochem Biophys Res Commun; 1999 Dec; 266(1):174-8. PubMed ID: 10581185
[TBL] [Abstract][Full Text] [Related]
54. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
55. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.
Bousette N; Patel L; Douglas SA; Ohlstein EH; Giaid A
Atherosclerosis; 2004 Sep; 176(1):117-23. PubMed ID: 15306183
[TBL] [Abstract][Full Text] [Related]
56. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
Flohr S; Kurz M; Kostenis E; Brkovich A; Fournier A; Klabunde T
J Med Chem; 2002 Apr; 45(9):1799-805. PubMed ID: 11960491
[TBL] [Abstract][Full Text] [Related]
57. Relationship of urotensin I induced vasodilatory action in rat thoracic aorta to Ca2+ regulation.
Itoh H; Lederis K
Can J Physiol Pharmacol; 1987 Mar; 65(3):298-302. PubMed ID: 3034389
[TBL] [Abstract][Full Text] [Related]
58. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.
Saetrum Opgaard O; Nothacker H; Ehlert FJ; Krause DN
Eur J Pharmacol; 2000 Oct; 406(2):265-71. PubMed ID: 11020490
[TBL] [Abstract][Full Text] [Related]
59. Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.
Lawson EC; Luci DK; Ghosh S; Kinney WA; Reynolds CH; Qi J; Smith CE; Wang Y; Minor LK; Haertlein BJ; Parry TJ; Damiano BP; Maryanoff BE
J Med Chem; 2009 Dec; 52(23):7432-45. PubMed ID: 19731961
[TBL] [Abstract][Full Text] [Related]
60. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism.
Giuliani L; Lenzini L; Antonello M; Aldighieri E; Belloni AS; Fassina A; Gomez-Sanchez C; Rossi GP
J Clin Endocrinol Metab; 2009 Feb; 94(2):684-90. PubMed ID: 19001524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
